Home » Stocks » VNRX

VolitionRX Limited (VNRX)

Stock Price: $4.46 USD 0.45 (11.22%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 214.96M
Revenue (ttm) 6,313
Net Income (ttm) -18.77M
Shares Out 47.03M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.46
Previous Close $4.01
Change ($) 0.45
Change (%) 11.22%
Day's Open 4.02
Day's Range 4.02 - 4.47
Day's Volume 403,218
52-Week Range 2.47 - 4.99


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 month ago

Volition is one of the sponsors for the upcoming Benzinga Global Small Cap Conference set to take place on December 8-9, 2020. Given the growing population, it is expected that the number of c...

Seeking Alpha - 1 month ago

VolitionRx began commercial sales of a blood test for pet cancer. There is no other product available on the market for testing cancer in dogs despite cancer being the leading cause of death f...

Business Wire - 6 months ago

DOUGLAS, Isle of Man--(BUSINESS WIRE)--Cotterford Co. Ltd. (“Cotterford”) the beneficial owner of approximately 26% of the outstanding shares of VolitionRX Limited (“Volition”) (AMEX: VNRX), t...

Seeking Alpha - 10 months ago

VolitionRx (VNRX) Investor Presentation - Slideshow

Seeking Alpha - 1 year ago

VolitionRx Limited's (VNRX) CEO Cameron Reynolds on Q3 2019 Results - Earnings Call Transcript

InvestorPlace - 1 year ago

These healthcare stocks are all worth a "buy" now. The healthcare sector will keep chugging along despite market volatility.

Other stocks mentioned: CATS, ENSG, FLGT, JYNT, NEO, VIEMF
Seeking Alpha - 1 year ago

VolitionRX Limited (VNRX) CEO Cameron Reynolds on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

VolitionRX Ltd. (VNRX) CEO Cameron Reynolds on Q4 2018 Results - Earnings Call Transcript

About VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRx Limited is headquartered in Austin, Texas.

Diagnostics & Research
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for VolitionRX stock is "Strong Buy." The 12-month stock price forecast is 7.16, which is an increase of 60.54% from the latest price.

Price Target
(60.54% upside)
Analyst Consensus: Strong Buy